Quantcast

Latest autoimmune diseases Stories

2014-05-29 08:29:17

RALEIGH, N.C., May 29, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the diagnosis and treatment of metabolic disease, announced today the appointment of Steven Delmar, CPA, as Chief Financial Officer. Mr. Delmar brings more than 35 years of financial and operational executive leadership experience to the company, serving most recently as Director of Business Operations at Computer Sciences Corporation (CSC)....

2014-05-28 16:27:04

ROME, May 28, 2014 /PRNewswire/ -- Sigma-Tau announces that Synacthen (R) (tetracosactide hexa-acetate salt) is now available again in most of the European countries. (Logo: http://photos.prnewswire.com/prnh/20140528/689733 ) Manufacturing challenges connected to tetracosactide over the past months caused the shortage of -Synacthen(R)- for patients throughout Europe and Sigma-Tau has devoted all its efforts in reestablishing the supply chain into these...

2014-05-26 11:13:00

UT Southwestern Medical Center A microRNA cluster believed to be important for suppressing colon cancer has been found to play a critical role in wound healing in the intestine, UT Southwestern cancer researchers have found. The findings, first discovered in mice and later reproduced in human cells, could provide a fresh avenue for investigating chronic digestive diseases and for potentially repairing damage in these and other disease or injury settings. "We identified a novel role...

2014-05-22 12:26:37

LONDON, May 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovationhttp://www.reportbuyer.com/pharma_healthcare/diseases/frontier_pharma_systemic_lupus_erythematosus_identifying_commercializing_first_in_class_innovation.html Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation SummaryThe Systemic Lupus...

2014-05-21 23:08:04

ReportsnReports.com adds “Crohn’s Disease Drug Market and Pipeline Analysis” report to its research store. Dallas, Texas (PRWEB) May 21, 2014 Under the umbrella of inflammatory bowel diseases, Crohn’s disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn’s disease in most cases affects the end of the small bowel (the ileum)...

2014-05-21 08:28:10

Tribute raises critically needed funds to support the Lupus Foundation of America's mission WASHINGTON, May 21, 2014 /PRNewswire-USNewswire/ -- Federal agency leaders, Members of Congress and national leaders from the chronic disease and disability communities gathered to pay Special Tribute to The Honorable Tom Harkin (D-IA), an unparalleled champion during his 30 years of public service for those affected by chronic disease and disability. The Tribute, held in Washington, DC on...

2014-05-21 04:21:29

DEERFIELD BEACH, Fla., May 21, 2014 /PRNewswire/ -- Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. The Gut Health Profile or, GHP, is a blood test profile that evaluates GI health and risks on a genetic, antibody and cellular level. The GHP may be of use to physicians in...

2014-05-20 20:22:08

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio((TM)) (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). ( ) "Entyvio is a new option that...

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-05-19 12:31:13

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Needhttp://www.reportbuyer.com/pharma_healthcare/treatments/gastrointestinal_therapeutics_asia_pacific_markets_2019_strong_potential_pipeline_biologics_account_high_regional_unmet_need.htmlGastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'